

Statistical approach enabling technology-specific assay interference prediction from large screening data sets

30 April 2024

Vincenzo Palmacci

Problem statement

-Thanks to their sensitivity and efficiency, **fluorescence-based assays are the most widely employed technology** for the high-throughput-screening (HTS) of compounds [1, 2].

-Despite the technical advantages brought to the field, fluorescence-based assays result in a significant number of **false positive readouts caused by assay interference** [3].

- If false readouts remain undetected, they may **trigger costly follow-up studies** that may eventually turn out as futile.

1. Macarron R. et al*. Impact of high-throughput screening in biomedical research*. Nat. Rev. Drug Discovery 2. https://atrandi.com/blog/fluorescence-assays-dominate-life-science-research

3. Sink R. et al. *False positives in the early stages of drug discovery.* Curr. Med Chem

The dominant readout: Fluorescence

"Fluorescence-based detection is the most used detection method in HTS: it is highly sensitive and has good signal-to-noise ratios. Fluorescence assays don't require special setups and can be miniaturized, which makes them ideal tools for screening applications."[3]

3. https://atrandi.com/blog/fluorescence-assays-dominate-life-science-research

Fields of application

-HITS TRIAGING:

The practice of selecting a compound series with a promising efficacy profile that meets basic safety requirements and to justify investment in its optimization [4].

-NEGATIVE DESIGN:

Battery of methods that are usually employed to eliminate molecules with undesired properties [5].

4. Vincent F. et al*. Hit Triage and Validation in Phenotypic Screening: Considerations and Strategies.* Cell Chem Bio 5. Yang Z. et al. *Application of Negative Design To Design a More Desirable Virtual Screening Library.* J. Med Chem

Agenda

PART 1. (~5 mins): **Introduction**

Introduction to miniaturized fluorescent assays in high-throughput-screening Overview of the main mechanisms of assay interference

PART 2. (~5 mins): **State-of-art**

Addressing assay interference: experimental and in-silico methodologies Addressing assay interference: pitfalls of existing approaches

PART 3. (~20 mins): **A new pipeline to predict assay interference** Building a comprehensive dataset from primary HTS screenings Identifying interfering compounds through analysis of compound activity rates Prediction of compounds likely to interfere with the assay technology

Fluorescence Intensity Assays (FLINT)

- Convenient for screening enzymatic inhibitors
- Fluorescent emission upon enzymatic

Fluorogenic assays Fluorescence polarization (FP)

- cleavage Detect dynamic interaction between the biological target and the ligand
	- Fluorescent emission upon interaction

Other popular fluorescence-based assay formats

• Fluorescence Resonance Energy Transfer (FRET)

Measures the energy transfer between a donor-acceptor pair. For the energy transfer to work donor and acceptor must be in close proximity.

• Time-Resolved FRET (TR-FRET)

Measures the time a fluorophore spends in the excited state before it reverts to its ground state by emitting a photon (FLT).

Pro of fluorescence-based assays

High specificity.

High sensitivity with low background noise.

Simple operation.

Credits: https://bpsbioscience.com/

No one's safe: false positive readouts

"Many hits are artefacts - their activity does not depend on a specific, drug-like interaction between molecule and protein. Artefacts have subversive reactivity that masquerades as drug-like binding and yields false signals across a variety of assays."[6]

Interfering compounds and interference mechanisms

6. Baell J. et al. *Chemical con artists foil drug* discovery. Nature

Dealing with assay interference: prevention measures and hit-triaging

Experimental countermeasures

- Screening with non-ionic detergents to prevent compounds aggregation
- Use of novel fluorophores emitting in a different region of the spectrum
- Use orthogonal assays to confirm the primary hits
- Implementation of counter-screen assays to identify interfering compounds

In-silico methodologies

Global methods:

HitDexter3, Pan-Assay interference compounds (PAINS)*

Specialized methods:

InterPred, ChemFluo, AZ (TR-)FRET interference classifiers

Specialized methods: ChemFluo

7. Yang Z. et al. *ChemFLuo: a web-server for structure analysis and identification of fluorescent compounds.* Briefings in Bioinformatics

Specialized methods: InterPred

8. Borrel A. et al*. InterPred: a webtool to predict chemical autofluorescence and luminescence interference.* Nucleic Acids Research.

Overview of existing methods

- Two Extreme Gradient Boosting (XGBoost) ensembles
- Prediction of autofluorescence in **blue and green channels**
- Trained and tested on **counter-screen data**
- Underwhelming performances on external test set (**MCC=0.34**) using the **same experimental evidence used in training**

ChemFluo AZ (TR-)FRET interference classifiers and interPred

- Random Forest Classifier (RFC)
- Prediction of i**nterference in AlphaScreen, FRET and TR-FRET** assays
- Trained and tested on **counter-screen data** from AstraZeneca
- Underwhelming performances on public test dataset (**MCC=0.20**)

- 13 Random Forest Classifiers (RFCs)
- Prediction of autofluorescence in the **blue, green and red channels**
- Trained validated and tested on random splits of the same dataset
- **• Uses counter-screen data produced ad-hoc**
- Each is model specific for one assay
- **• Not possible to assess their performances** due to testing strategy used

A new methodology to identify compounds interfering with fluorescent assays

Overview

Data collection: Bayer AG HTS historical data

Dataset composition

• Compounds:

More than 5 millions compounds represented by canonical SMILES strings.

• Assays:

500 different assays (different technology, biological target).

• Readouts:

Preprocessed bioactivity readouts received from experimentalists as Z-scores

To my knowledge, this represent the largest HTS primary screening dataset available both in public and private domain.

Data preprocessing: Bayer AG HTS historical data

Preprocessing pipeline

1. Assays must have bioactivity recorded

for at least 80% of the compounds

2. Compounds must have bioactivity recorded for at least 80% of the assays

Dataset composition after step 1 and 2:

205 assays, 1'488'407 compounds

- **3.** Assays must be annotated
- **4.** Compounds must be unique (SMILES strings matching)
- **5.** Binarize Z-scores following experimentalist indications

Data preprocessing: Bayer AG HTS historical data

Dataset split prior to modelling

- **1.** Compute Murcko scaffolds
- **2.** Group molecules sharing the same scaffold
- **3.** Random assignment of grouped molecules to training (80%), validation (10%) and test (10%) set.

Splits sizes:

Train: 1'130'711

Validation: 135' 830

Test: 174'493

Dataset characterization: Bayer AG HTS historical data

Chemical space

PCA comparing the training set chemical space (BLUE) and the DrugBank approved drugs space (RED)

Data collection and preprocessing: PubChem test set

*As you may notice someone did a mess and wrote 3 times the same assay ID. This show that Supplementary materials should never be overlooked.

Dataset characterization: PubChem test set

Core work: labelling compounds likely to interfere with fluorescence-based assays

Labelling compounds likely to interfere with the assay technology: compute interference metrics

Activity-to-tested ratio (ATR)

Activity-to-tested ratio is computed as:

 $ATR^i = \frac{\# \text{ active readouts}}{\# \text{ time selected}}$ Where i is the i-th compound in the dataset

1. Compute compounds ATR:

- ATR in fluorescence assays \bullet
- ATR in other assays \bullet
- 2. Apply threshold to obtain binary interference labels

reloaded Noise-to-active ratio (NAR) Fisher exact test

Noise-to-active ratio is computed as:

active back \cap # active main $NAR^i =$ # times tested Where i is the i-th compound in the dataset 1. Compute compounds NAR considering only fluorescent assays 2. Apply threshold to obtain binary interference labels

For the compound contingency table X:

1. Compute compounds p-values applying

Fisher –exact test

2. Apply threshold to obtain binary

interference labels

Labelling compounds likely to interfere with the assay technology: compute binary labels

Thresholds applied to compute binary interference labels

Rationale applied to interference metrics to compute binary labels

 $ATRⁱ_{Fluo} \geq mean(ATR_{other}) + thresh * std(ATR_{other})$

 $NAR^{i} \geq thresh$

 $p^i \leq thresh$

Labelling compounds likely to interfere with the assay technology: comparison of labelling strategies

20% threshold:

niversität

- ATR is a superset of NAR
- Fisher recognize a different set of compounds as interfering

2% threshold:

- Higher relative size of overlap among all methods
- NAR is not a subset of ATR anymore

26

Development of machine learning classifiers for assay interference prediction

niversität

RFC

BalancedRandomForest (imbalanced-learn) BayesOpt 50 iterations

Hyperparameters optimized:

- n_estimators
- max depth
- bootstrap

MLP (PyTorchLightning)

ELU activation function BinaryCrossEntropyLoss WeightedRandomSampler

Optuna 50 iterations

Hyperparameters optimized:

- n layers
- n units
- dropout
- learning_rate

27

Have fun reading the tables

Optimized hyperparameters: RFC

NAR

Have fun reading

Optimized hyperparameters: MLP

the tables

ATR

FISHER

29

Model performances on the Bayer AG test set

Model performances on the Bayer AG test set

MLP MCC for different labelling methods

Model performances on the PubChem derived test set

Model performances on the PubChem derived test set

RFC MCC for different labelling methods

Analysis of performances on the PubChem derived test set

TMAP of PubChem test set compounds colored by PubChem activity label (BLUE non-autofluorescent, RED autofluorescent)

TMAP of PubChem test set compounds colored by predicted interference label (BLUE non-interfering, RED interfering)

Conclusions

- **• Single-dose HTS** data can be used with very **little preprocessing** to address assay interference
- We show that statistically derived labels can be used to train ML models for prediction of assay interference (best model reaching **MCC=0.47** on the internal test set)
- The interference labels obtained using ATR, NAR, and Fisher exact test can **approximate experimental evidence**
- Our best model **outperforms existing methods** for the prediction of autofluorescent compounds (**MCC=0.45** on the external test set)

Additional experiments

- Explore if the models can predict other type of interference (e.g. aggregation)
- Find additional public available datasets to further assess the models applicability
- Extend the approach to other assay technologies

